Table 3 The univariate analyses of the association between patients prognosis and clinicopathological valiables
From: Soluble Neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors
Clinicopathological valiables | No | 5-year disease-free survival rate (%) | p Value 3 | No | 5-year local recurrence-free survival rate (%) | p Value 3 | No | 5-year metastasis-free survival rate (%) | p Value 3 | No | 5-year overall survival rate (%) | p Value 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | ||||||||||||
≦49 | 23 | 60.9% | 0.1603 | 25 | 90.0% | 0.0621 | 32 | 58.9% | 0.5899 | 32 | 81.8% | 0.0517 |
≧50 | 32 | 30.5% | 31 | 62.4% | 40 | 46.1% | 41 | 56.0% | ||||
Gender | ||||||||||||
Male | 26 | 50.2% | 0.5806 | 29 | 76.1% | 0.6890 | 36 | 60.4% | 0.4844 | 36 | 68.8% | 0.7350 |
Female | 29 | 35.4% | 27 | 76.5% | 36 | 44.8% | 37 | 66.1% | ||||
Size (cm) | ||||||||||||
<5 | 14 | 66.1% | 0.0616 | 13 | 82.5% | 0.9879 | 17 | 43.5% | 0.0159 | 17 | 83.3% | 0.1327 |
≧5 | 41 | 34.5% | 43 | 73.4% | 55 | 79.5% | 56 | 63.0% | ||||
Depth | ||||||||||||
Superficial | 3 | 66.7% | 0.8647 | 3 | 66.7% | 0.6414 | 6 | 62.5% | 0.6888 | 6 | 75.0% | 0.7062 |
Deep | 52 | 42.1% | 53 | 76.9% | 66 | 51.0% | 67 | 66.7% | ||||
Location 1 | ||||||||||||
Trunk | 16 | 34.4% | 0.2593 | 13 | 65.6% | 0.3231 | 24 | 54.7% | 0.8741 | 25 | 69.4% | 0.7125 |
Extremity | 37 | 48.9% | 43 | 77.9% | 46 | 52.7% | 46 | 67.1% | ||||
Histological grading | ||||||||||||
Low grade | 13 | 69.2% | 0.1171 | 13 | 100% | 0.1026 | 14 | 84.6% | 0.0108 | 14 | 91.7% | 0.0426 |
High grade | 42 | 31.4% | 43 | 67.2% | 58 | 58.4% | 59 | 60.5% | ||||
Soluble Cadherin 2 | ||||||||||||
Low | 40 | 55.1% | 0.0022 | 40 | 83.5% | 0.0123 | 51 | 51.0% | 0.0107 | 52 | 73.0% | 0.0334 |
High | 15 | 0% | 16 | 60.6% | 21 | 34.9% | 21 | 50.4% |